Clinical Trial Update: Testing the Effect of M1774 on Hard-to-Treat Refractory SPOP-mutant Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating M1774 in hard-to-treat prostate cancer is currently active but not recruiting. The study targets castration-resistant and metastatic ca…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• M1774

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Castration-Resistant Prostate Carcinoma, Metastatic Castration-Resistant Prostate Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING